#South Korea #Seoul #IPF #Daewoong #Bersiporocin

Latest Developments in IPF Drug Research

Daewoong Pharmaceutical has recently shared significant insights from a global Phase 2 clinical trial for its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), during the European Respiratory Society (ERS) Congress held on September 6, 2026. The trial, which aims to evaluate the drug's efficacy in treating this debilitating lung disease, included a diverse group of 104 patients from both South Korea and the United States.

Introduction to Bersiporocin

Bersiporocin is a pioneering prolyl-tRNA synthetase (PRS) inhibitor designed to combat the excessive collagen production linked with IPF. This condition is characterized by the lung's gradual scarring, which can severely impact a patient's breathing capacity. The drug’s unique mechanism of action involves inhibiting collagen synthesis, directly addressing the fibrotic signals that exacerbate the disease. Unlike traditional antifibrotic therapies, Bersiporocin aims to modify the underlying pathogenesis of IPF.

Trial Overview

The global Phase 2 trial is a randomized, double-blind, placebo-controlled study that examines the drug’s performance over a 24-week period. Patients received either the drug or a placebo twice a day, and those already on existing antifibrotics, such as pirfenidone or nintedanib, were also included. Such inclusivity in the trial design reflects real-world treatment scenarios where patients may receive combined therapies.

Baseline Characteristics of Participants

The analysis of the baseline characteristics revealed that out of the enrolled patients, 55 (52.9%) hailed from South Korea, while 49 (47.1%) were from the US. Notably, 71 patients (68.3%) were receiving background antifibrotic therapy at the trial's commencement, indicating a robust representation of both treatment-naïve and experienced patients. The mean forced vital capacity (FVC) was measured at approximately 77% predicted, with the diffusing capacity for carbon monoxide (DLCO) measured at about 51% predicted. This data provides critical context for interpreting further efficacy results.

Importance of the Findings

The presentation of these findings was significant, as it offered a deeper understanding of the disease's severity among participants and establishes a foundation for interpreting efficacy and safety in subsequent trials. The fact that a substantial portion of patients was receiving background therapy illustrates the common clinical challenge of managing IPF while also exploring new treatment avenues.

Future Directions

Looking ahead, Daewoong Pharmaceutical anticipates releasing top-line Phase 2 results within the first half of 2027. Such results will be pivotal for both the ongoing evaluation of Bersiporocin and its development trajectory. Additionally, the drug has already been designated as an Orphan Drug and received Fast Track status from the U.S. FDA, marking a promising step in its journey toward potential market approval.

Moreover, Professor Moo Suk Park from Severance Hospital, who was involved in the trial, expressed optimism about the findings, emphasizing their relevance in understanding patient profiles. CEO Seongsoo Park echoed this sentiment, noting that the successful completion of the trial enrollment and data presentation in such a prominent forum is a major milestone for the company and the drug’s development.

With the ongoing challenges posed by IPF and the need for effective therapeutic options, Bersiporocin's development represents a beacon of hope for patients and the medical community alike. As Daewoong Pharmaceutical navigates the next steps, stakeholders will remain eager to see this groundbreaking research unfold.